Cellectar Biosciences

$1.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-2.42%) Today
+$0.01 (+0.83%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell CLRB and other stocks, options, and ETFs commission-free!

About CLRB

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ. The listed name for CLRB is Cellectar Biosciences, Inc. Common Stock.

CEO
James V. Caruso
Employees
8
Headquarters
Florham Park, New Jersey
Founded
1996
Market Cap
32.44M
Price-Earnings Ratio
Dividend Yield
Average Volume
211.26K
High Today
$1.24
Low Today
$1.20
Open Price
$1.24
Volume
193.09K
52 Week High
$3.33
52 Week Low
$1.01

Collections

CLRB Earnings

-$0.76
-$0.51
-$0.25
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 8, Pre-Market

You May Also Like